Publications by authors named "Maria I Antonangeli"
Nerve growth factor (NGF) plays a critical neuroprotective role in retinal health, supporting neuronal survival and regeneration. Recombinant human NGF (rhNGF) holds promise for treating retinal degenerative diseases such as glaucoma, retinitis pigmentosa, and optic neuropathies. However, efficient retinal delivery of rhNGF remains a major challenge due to anatomical barriers and rapid clearance from conventional routes.
View Article and Find Full Text PDFThus far, no manufacturing process able to support industrialization has been reported for the recombinant human brain-derived neurotrophic factor (rhBDNF). Here, we described the setup of a new protocol for its production in () and its purification to homogeneity. A synthetic gene, codifying for the neurotrophin precursor, was inserted into an expression vector and transformed into BL21 (DE3) strain.
View Article and Find Full Text PDFArticle Synopsis
- BDNF plays an important role in brain function and may help with pain and depression; this study tested its effectiveness against migraines using an animal model.
- Researchers administered two doses of recombinant human BDNF (rhBDNF) to rats with pain induced by NTG injections, measuring pain response and changes in brain-related neuropeptides and cytokine levels.
- Results showed that rhBDNF significantly reduced migraine-related pain and altered gene expression similarly to the migraine medication sumatriptan, indicating its potential as a non-invasive migraine treatment.
Background And Objectives: Nerve growth factor (NGF) is a neurotrophin with therapeutic possibilities that extend from the nervous system to the eye. We tested the safety, maximal tolerated dose, pharmacokinetics, and antigenicity of a novel human recombinant NGF (rhNGF) eye-drop formulation in a phase I study.
Methods: This prospective, randomized, double-masked, vehicle-controlled trial, sponsored by Dompé SpA (registered as NCT01744704 at ClinicalTrials.